Related Experiment Video
Updated: Oct 23, 2025
DNA Vector-based RNA Interference to Study Gene Function in Cancer
Published on: June 4, 2012
Assessment of In Vivo siRNA Delivery in Cancer Mouse Models
Lingegowda S Mangala1,2, Cristian Rodriguez-Aguayo2,3, Emine Bayraktar1,2
1Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center (MDACC), Houston, TX, USA.
Abstract:
RNA interference (RNAi) has rapidly become a powerful tool for target discovery and therapeutics. Small interfering RNAs (siRNAs) are highly effective in mediating sequence-specific gene silencing. However, the major obstacle for using siRNAs for cancer therapeutics is their systemic delivery from the administration site to target cells in vivo. This chapter describes approaches to deliver siRNA effectively for cancer treatment and discusses in detail the current methods to assess pharmacokinetics and biodistribution of siRNAs in vivo.
Insights
Small interfering RNAs (siRNAs) offer potent gene silencing for cancer therapy. Effective in vivo delivery remains a challenge, but this chapter details methods to overcome this hurdle and assess siRNA pharmacokinetics.
Area of Science:
- Biotechnology
- Molecular Biology
- Cancer Therapeutics
Background:
- RNA interference (RNAi) utilizes small interfering RNAs (siRNAs) for sequence-specific gene silencing.
- siRNAs are promising for cancer therapeutics due to their gene silencing capabilities.
Purpose of the Study:
- To describe effective siRNA delivery approaches for cancer treatment.
- To discuss methods for assessing siRNA pharmacokinetics and biodistribution in vivo.
Main Methods:
- Review of current siRNA delivery strategies for cancer.
- Detailed discussion of pharmacokinetic and biodistribution assessment techniques for siRNAs.
Main Results:
- Identified key challenges in systemic siRNA delivery for cancer.
- Outlined various methods for enhancing siRNA delivery efficacy.
- Presented approaches for evaluating siRNA behavior in vivo.
Conclusions:
- Effective in vivo delivery is crucial for siRNA-based cancer therapeutics.
- Understanding pharmacokinetics and biodistribution is essential for successful siRNA therapy development.
